Patent · US Active

Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido

US8349820B2 · kind B2 · utility

52Cited by

23References

6Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Susan Zeun · Berlin, DE
Holger Zimmermann · Falkensee, DE
Susanne Parke · Berlin, DE

Key dates

Filing date	Oct 17, 2007
Grant date	Jan 8, 2013
Priority date	—
Expiry date	Jun 16, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use, optionally together with oral contraception, of estradiol valerate or 17β-estradiol in combination with 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) in a multistage or single-stage combination preparation for oral therapy to maintain and/or increase feminine libido.The total number of daily dose units of the multistage combination and of a pharmaceutically harmless placebo or a single-stage combination and optionally the pharmaceutically harmless placebo-containing or placebo- and hormone-free daily dose units amounts to 28 daily dose units.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.